[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
February 25, 2004

Coupling Drug and Catheter Therapy for Myocardial Infarction

Author Affiliations

Author Affiliation: Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio.

JAMA. 2004;291(8):1000-1002. doi:10.1001/jama.291.8.1000

Notwithstanding efficacy demonstrated in randomized trials, reperfusion strategies for acute myocardial infarction (MI) remain subject to considerable limitations. A plateau of mortality reduction seemingly has been reached with fibrinolytic therapy,1 a lack of progress that may relate to the apparent "ceiling" of coronary patency achieved with these drugs, reocclusion, or impaired microvascular tissue level reperfusion. Moreover, the catastrophic complication of intracranial hemorrhage continues to occur in up to 1% of patients receiving fibrinolytic agents.1 Mechanical approaches to revascularization with balloon angioplasty or coronary stenting overcome some limitations of pharmacologic reperfusion, as randomized trials comparing fibrinolysis with primary percutaneous coronary intervention (PCI) in general have shown the latter to be associated with lower rates of death or reinfarction and markedly diminished hemorrhagic complications.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×